Selected article for: "acute rejection and lung rejection"
Author: Nordén, Rickard; Magnusson, Jesper; Lundin, Anna; Tang, Ka-Wei; Nilsson, Staffan; Lindh, Magnus; Andersson, Lars-Magnus; Riise, Gerdt C; Westin, Johan
Title: Quantification of Torque Teno Virus and Epstein-Barr Virus Is of Limited Value for Predicting the Net State of Immunosuppression After Lung Transplantation
  • Document date: 2018_3_6
    • ID: zhlvvuj4_43
    Snippet: EBV has previously been suggested as a surrogate marker for immunosuppression as an association between elevated EBV-DNA levels and reduced incidence of acute rejection of lung transplants was observed [23] . In addition, EBV-DNA was safely used as a trigger for reduction of immunosuppression late after lung transplantation and was found to be associated with a shorter time to development of infectious complications or solid tumors, but not PTLD .....
    Document: EBV has previously been suggested as a surrogate marker for immunosuppression as an association between elevated EBV-DNA levels and reduced incidence of acute rejection of lung transplants was observed [23] . In addition, EBV-DNA was safely used as a trigger for reduction of immunosuppression late after lung transplantation and was found to be associated with a shorter time to development of infectious complications or solid tumors, but not PTLD [24, 42] . We found no association between EBV-DNA and acute rejection at any time during FU. A direct comparison could, however, be hampered by the fact that EBV-DNA was analyzed in this study, and EBV-encoded RNA in an earlier study [23] .

    Search related documents:
    Co phrase search for related documents
    • acute rejection and immunosuppression reduction: 1, 2, 3
    • acute rejection and infectious complication: 1, 2
    • acute rejection and lung transplant: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
    • acute rejection and lung transplant acute rejection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute rejection and lung transplantation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute rejection and short time: 1
    • direct comparison and early study: 1, 2, 3
    • direct comparison and reduce incidence: 1
    • direct comparison and short time: 1, 2, 3
    • direct comparison and study analyze: 1
    • early study and lung transplant: 1, 2, 3
    • early study and lung transplantation: 1, 2, 3
    • early study and reduce incidence: 1, 2, 3, 4, 5, 6
    • early study and short time: 1, 2, 3, 4, 5
    • early study and solid tumor: 1, 2
    • early study and study analyze: 1, 2, 3, 4, 5, 6, 7, 8
    • early study and surrogate marker: 1
    • EBV DNA level and FU time: 1